What is STALEVO?
STALEVO is a therapy for people with Parkinson’s disease (PD). In addition to carbidopa and levodopa (active ingredients in levodopa (active ingredients in Sinemet®*), STALEVO contains entacapone (active ingredient in COMTAN®), a substance that enhances the benefits of levodopa.

Levodopa is the most widely prescribed treatment for PD. In clinical studies, the combination of entacapone, carbidopa, and levodopa provided longer control of PD symptoms compared with carbidopa and levodopa alone. This means that when you take STALEVO, you may get more out of your daily activities over a longer period of time.

STALEVO can be used instead of carbidopa/levodopa and COMTAN by patients taking those medicines as separate tablets. Depending on your levodopa dose and side effects, STALEVO can also be used to replace carbidopa/levodopa when the benefits of levodopa aren't lasting as long as they used to.

STALEVO is supplied in 3 strengths

STALEVO 50, containing 12.5 mg carbidopa, 50 mg levodopa, and 200 mg entacapone

STALEVO 100, containing 25 mg carbidopa, 100 mg levodopa, and 200 mg entacapone

STALEVO 150, containing 37.5 mg carbidopa, 150 mg levodopa, and 200 mg entacapone

Please ask your healthcare professional if STALEVO is appropriate for you.

How is STALEVO different from other levodopa therapies?
STALEVO is a levodopa therapy. The difference between STALEVO and other levodopa therapies is that STALEVO also contains entacapone. Entacapone helps levodopa last longer by blocking a substance in the body called a COMT enzyme. This enzyme breaks down levodopa before it reaches the brain. When less levodopa is broken down, more is available to the brain. Increased availability of levodopa may lead to smoother and steadier levels of dopamine in the brain, which may provide better symptom control for longer periods each day. This may lead to improvement in daily activities.

Also in this Section:
How STALEVO Works
FAQs